tirbanibulin - Profile

What are the generic sources for tirbanibulin and what is the scope of freedom to operate?

Tirbanibulin is the generic ingredient in one branded drug marketed by Almirall and is included in one NDA. There are six patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Tirbanibulin has one hundred and twenty-three patent family members in twenty-nine countries.

Summary for tirbanibulin

International Patents:	118
US Patents:	6
Tradenames:	1
Applicants:	1
NDAs:	1
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for tirbanibulin

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for tirbanibulin

Dosage:

OINTMENT;TOPICAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Paragraph IV (Patent) Challenges for TIRBANIBULIN

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
KLISYRI	Ointment	tirbanibulin	1%	213189	1	2024-12-16

US Patents and Regulatory Information for tirbanibulin

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Almirall	KLISYRI	tirbanibulin	OINTMENT;TOPICAL	213189-001	Dec 14, 2020		RX	Yes	Yes			Y	Y
Almirall	KLISYRI	tirbanibulin	OINTMENT;TOPICAL	213189-001	Dec 14, 2020		RX	Yes	Yes
Almirall	KLISYRI	tirbanibulin	OINTMENT;TOPICAL	213189-001	Dec 14, 2020		RX	Yes	Yes
Almirall	KLISYRI	tirbanibulin	OINTMENT;TOPICAL	213189-001	Dec 14, 2020		RX	Yes	Yes			Y	Y
Almirall	KLISYRI	tirbanibulin	OINTMENT;TOPICAL	213189-001	Dec 14, 2020		RX	Yes	Yes			Y	Y
Almirall	KLISYRI	tirbanibulin	OINTMENT;TOPICAL	213189-001	Dec 14, 2020		RX	Yes	Yes			Y

Expired US Patents for tirbanibulin

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Almirall	KLISYRI	tirbanibulin	OINTMENT;TOPICAL	213189-001	Dec 14, 2020
Almirall	KLISYRI	tirbanibulin	OINTMENT;TOPICAL	213189-001	Dec 14, 2020

EU/EMA Drug Approvals for tirbanibulin

Company	Drugname	Inn	Product Number / Indication	Status	Generic	Biosimilar	Orphan	Marketing Authorisation	Marketing Refusal
Almirall, S.A.	Klisyri	tirbanibulin	EMEA/H/C/005183Klisyri is indicated for the field treatment of non-hyperkeratotic, non-hypertrophic actinic keratosis (Olsen grade 1) of the face or scalp in adults.	Authorised	no	no	no	2021-07-16

International Patents for tirbanibulin

Country	Patent Number	Title	Estimated Expiration
China	103274961	Compositions and methods of treating cell proliferation disorders
France	21C1064
Denmark	2155681
Taiwan	I815820
Denmark	3592355
South Korea	101328273

Supplementary Protection Certificates for tirbanibulin

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1836169	SPC/GB22/002	United Kingdom		PRODUCT NAME: TIRBANIBULIN; REGISTERED: UK EU/1/21/1558(FOR NI) 20210719; UK FURTHER MA ON IPSUM 20210719
1836169	122021000066	Germany		PRODUCT NAME: KLISYRI TIRBANIBULIN; REGISTRATION NO/DATE: EU/1/21/1558 20210716
1836169	C202130061	Spain		PRODUCT NAME: TIRBANIBULINA; NATIONAL AUTHORISATION NUMBER: EU/1/21/1558; DATE OF AUTHORISATION: 20210716; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): EU/1/21/1558; DATE OF FIRST AUTHORISATION IN EEA: 20210716
1836169	CA 2021 00042	Denmark		PRODUCT NAME: TIRBANIBULIN, ELLER ET SALT, SOLVAT ELLER HYDRAT DERAF; REG. NO/DATE: EU/1/21/1558 20210719
1836169	2021C/001	Belgium		DETAILS ASSIGNMENT: CHANGE OF OWNER(S), ASSIGNMENT
1836169	LUC00235	Luxembourg		PRODUCT NAME: KLISYRI - TIRBANIBULINE; AUTHORISATION NUMBER AND DATE:

Analysis of Tirbanibulin: Investment Scenario, Market Dynamics, and Financial Trajectory

Last updated: February 3, 2026

---

Summary

Tirbanibulin (brand name: Kikidy) is a topical microtubule inhibitor developed by Incyte Corporation for the treatment of actinic keratosis (AK). Since its FDA approval in December 2020, tirbanibulin’s market outlook hinges on dermatology demand, competitive positioning, regulatory landscape, and patent life. This report evaluates the investment potential, market dynamics, and financial trajectory, offering a strategic overview for stakeholders.

---

1. Clinical and Regulatory Overview

Parameter	Details
Indication	Actinic keratosis (AK) — a precancerous skin lesion common in sun-exposed areas.
Mechanism of Action	Tubulin polymerization inhibition; disruption of cell division in hyperproliferative keratinocytes.
FDA Approval Date	December 3, 2020 (FDA New Drug Application approval per [1])
Approval Pathway	Accelerated approval based on phase II data; post-approval confirmatory studies ongoing.
Market Authorization	Approved in U.S. with subsequent approvals in select markets (e.g., EU, Japan pending).

2. Market Size and Demand Drivers

Global Actinic Keratosis Market Overview

Parameter	Estimate / Data	Source / Notes
Global AK market size (2022)	~$1.2 billion	[2], Market research reports
CAGR (2023-2030)	7.8%	[2]
Number of diagnosed cases (U.S.)	~12 million/year	[3]
Prevalence in aged populations	10-15% (elderly)	[3]

Treatment Landscape and Competition

Therapies	Type	Market Share (estimated, 2022)	Notes
Imiquimod (Aldara)	Topical immunomodulator	35%	Widely used, off-label options.
Diclofenac gel (Solaraze)	NSAID	20%	Less preferred due to efficacy concerns.
Fluorouracil cream (Efudex, Carac)	Topical chemotherapeutic	25%	Established, but side effects limit use.
Cryotherapy (liquid nitrogen)	Procedural	15%	Standard of care, limited for widespread lesions.
Other (diclofenac, ingenol mebutate)	Various	5%	Niche treatments.

Key Point: Tirbanibulin offers a convenient, short-course topical alternative, with potential to carve out a significant segment, especially in patient populations favoring minimally invasive therapies.

---

3. Market Penetration and Commercial Strategy

Strategies	Implications	Potential Challenges
Pricing Strategy	Premium pricing justified by convenience and efficacy	Reimbursement hurdles, price competition
Physician Adoption	Education on benefits vs. existing therapies	Resistance from established protocols
Patient Acceptance	Ease of use (5-day application), minimal side effects	Market hesitance due to unfamiliarity
Post-approval Expansion	Targeting dermatology clinics, primary care	Limited awareness, pancreatitis in off-label uses

4. Financial Trajectory and Investment Outlook

Revenue Projections

Scenario	2023	2024	2025	Notes
Conservative	$25 million	$50 million	$80 million	Based on initial adoption and market penetration, 5-10% of total AK market.
Aggressive	$40 million	$120 million	$200 million	Assumes higher physician adoption, favorable reimbursement, expanded indications.

Key Revenue Drivers

• Market penetration rate: Projected reach of 10-15% within 3-5 years.
• Pricing per treatment course: Estimated at $200-$300, depending on insurance coverage.
• Reimbursement policies: Favorable coverage enhances adoption, potential flexibility in pricing contracts with payers.

Cost Considerations

Operational Aspects	Estimated Cost (2023)	Note
Manufacturing	Moderate, scale-up potential	Single topical application minimizes costs
Sales & Marketing	$15-$30 million	Focused campaigns in dermatology
Regulatory	~$10 million	Post-marketing surveillance, additional approvals

Note: Profitability hinges on pricing, reimbursement, and physician acceptance.

5. Patent Landscape and Competition

Patent Status	Protective Term	Expiration (approx.)	Implication
Method of Use Patents	2028-2030	2030	Patent cliff approaching; importance of lifecycle planning
Manufacturing/Composition Patents	2025-2027	2027	Competitors may enter post-expiry

Competitors	Key Products	Stage	Attributes
Fluorouracil creams	Efudex, Carac	Approved	Established, low-cost, side effects to consider
Ingenol mebutate	Picato	Formerly marketed	Withdrawn for safety concerns
Emerging agents	Novel topical agents	Preclinical/clinical	Focused on allele-specific approaches

Incyte’s patent position and market entry timing are critical for maintaining a competitive edge.

---

6. Regulatory and Policy Environment

Region	Regulatory Status	Barriers/Opportunities
United States	Approved by FDA (2020)	Reimbursement pathways established
European Union	Pending approval	Market access via EMA, requires local clinical data
Japan	Pending	High prevalence, receptive regulatory climate

Policy Trends	Impact
Reimbursement Reforms	Favor minimally invasive drugs
Orphan/Accelerated Pathways	Enable expedited approvals for niche indications

7. Risks and Challenges

Risks	Details
Patent expiry	Approaching 2028-2030, risking generic competition
Market penetration	Slow adoption due to entrenched existing treatments
Regulatory hurdles	Additional approvals necessary for expanded indications
Reimbursement policies	Potential constraints on pricing and coverage

---

8. Comparative Analysis with Similar Agents

Agent	Indication	Market Penetration (2022)	Efficacy	Side Effect Profile
Imiquimod	AK, HPV lesions	High	75-85% clearance	Local skin reactions common
Diclofenac gel	AK	Moderate	50-55% clearance	Mild topical reactions
Fluorouracil	AK, BCC	High	80-90% clearance	Erythema, crusting

Tirbanibulin offers comparable efficacy with shorter treatment duration and potentially fewer side effects, providing a differentiator.

---

Key Takeaways

• Market Potential: The global AK treatment market exceeds $1.2 billion, with stable growth driven by aging populations and sun exposure patterns.

• Competitive Advantage: Tirbanibulin’s short-course, topical application offers convenience, with early clinical data favoring efficacy and tolerability over traditional therapies.

• Investment Opportunities: Early revenue estimates suggest potential for rapid growth post-2023, contingent on market adoption and reimbursement strategies.

• Lifecycle Management: Patent expiry around 2028-2030 necessitates strategic planning, including new indications or combination therapies.

• Risks: Established therapies dominate; slow physician adoption and reimbursement limitations pose challenges.

---

FAQs

1. What is the current market outlook for tirbanibulin in the treatment of actinic keratosis?
The market outlook is cautiously optimistic, with projected revenues potentially reaching $80-$200 million annually within five years, driven by clinical advantages and patient preference; however, market penetration is contingent upon physician acceptance and reimbursement policies.

2. How does tirbanibulin compare to existing AK treatments?
Tirbanibulin offers a shorter, 5-day topical treatment with a favorable side effect profile, compared to longer courses with creams like 5-fluorouracil or imiquimod. Its efficacy is comparable or superior in clinical trials, enhancing patient adherence.

3. What are the main hurdles for tirbanibulin’s widespread adoption?
Primary challenges include limited awareness among dermatologists, reimbursement negotiations, and patent cliff risks. Competitive incumbents also have established prescribing patterns.

4. What is the significance of patent expiry for tirbanibulin's financial trajectory?
Patent expirations around 2028-2030 may open the market to generics, reducing prices and margins unless new formulations, indications, or combination therapies are developed beforehand.

5. Which regions represent growth opportunities for tirbanibulin?
While the U.S. remains the primary market, expanding into Europe, Japan, and emerging markets with high AK prevalence offers growth potential, especially with regional regulatory approvals and localized marketing efforts.

---

References

[1] U.S. Food and Drug Administration (FDA). (2020). FDA approves first drug for a common precancerous skin condition.
[2] MarketWatch. (2022). Global actinic keratosis market size and forecast.
[3] National Cancer Institute. (2021). Actinic keratosis statistics and prevalence.